Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma

BACKGROUND: Nab-paclitaxel–gemcitabine combination significantly improved overall survival over gemcitabine in metastatic pancreatic adenocarcinoma. A phase 1b trial was performed (ClinicalTrials.gov number, NCT01730222) to determine the recommended phase 2 dose (RP2D) of nab-paclitaxel in combinati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Reni, Michele, Balzano, Gianpaolo, Zanon, Silvia, Passoni, Paolo, Nicoletti, Roberto, Arcidiacono, Paolo Giorgio, Pepe, Gino, Doglioni, Claudio, Fugazza, Clara, Ceraulo, Domenica, Falconi, Massimo, Gianni, Luca
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4973162/
https://ncbi.nlm.nih.gov/pubmed/27404453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.209
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados